Garvey Institute news | April 30, 2022
Our Innovation Grants Program launched in 2020 funded a project led by Kristen Lindgren, PhD, ABPP and Michele Bedard-Gilligan, PhD, called “Improving Washingtonians’ resilience and recovery from traumatic events with a Trauma-Informed Care ECHO Clinic”.
Garvey Institute news | April 30, 2022
Our Innovation Grants Program launched in 2020 funded a project led by Amy Starosta, PhD, Jeanne Hoffman, PhD, and Kari Stephens, PhD, called “Opioid prescription and use following traumatic brain injury”.
The Seattle Times | April 23, 2022
Scientists, doctors, advocacy workers, and other community members gathered to discuss the next frontier of treating substance-use disorders and addiction: psychedelics. The meeting was convened by the Center for Novel Therapeutics in Addiction Psychiatry led by Nathan Sackett, MD and was sponsored, in part, by the Garvey Institute for Brain Health Solutions.
Department news | April 21, 2022
A growing body of research suggests that the use of psychedelic compounds combined with behavioral interventions may provide powerful treatment options for a range of addictions including alcohol use disorder, opioid use disorder, tobacco use disorder and others.
ARDC News | March 17, 2022
Debby Tsuang, MD, MSc, and her team are researching the best remote health tools to assess mental health symptoms for African Americans and better include them in research. Written by Lori Mae Yvette Calibuso Acob, Brain Health Science Writing intern at the Garvey Institute for Brain Health Solutions.
Department news | January 31, 2022
The Garvey Institute for Brain Health Solutions reached a milestone by holding its first Annual Meeting.
The Seattle Times | January 5, 2022
Marco Pravetoni, PhD, with funding from The Garvey Institute for Brain Health Solutions, will lead UW Medicine’s new Center for Medication Development for Substance Use Disorders. He and collaborators in New York and New Jersey are running the first-ever opioid vaccine trial in humans in the U.S.
Department news | December 28, 2021
The ECHO (Extension for Community Healthcare Outcomes) model uses a virtual educational lecture series and patient case discussion to improve provider preparedness to treat patients and improve patient outcomes. Our latest ECHO launch will test whether the model can enhance the care of traumatic brain injury (TBI).
KING 5 | November 17, 2021
A Mountlake Terrace clinic is using a novel therapy on some patients with treatment-resistant mental health challenges — but is it safe? Nathan Sackett, PhD, says psychedelics are only truly therapeutic when combined with professional psychotherapy.
Right as Rain | November 15, 2021
Microdosing psilocybin has become trendy among people hoping to alleviate anxiety or increase creativity. Nathan Sackett, MD, talks about its promise as a therapeutic agent and his plans to build a novel therapeutics research program that will explore the pairing of compounds like psilocybin and ketamine with behavioral interventions to treat addictions.